The state Supreme Court has declined to hear the appeal of a class of plaintiffs fighting a decertification order in an off-label marketing case against drug maker Pfizer.

That leaves stand a January Superior Court ruling that determined the proposed class, in a case regarding Pfizer’s alleged off-label marketing of an epilepsy drug, was properly decertified when Pfizer presented new evidence that the main expert for the class didn’t prove class members’ individual doctors relied on the marketing.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]